title: The Food and Drug Administration decision not to approve the 110 mg dose of dabigatran: give us a way out.
authors.forename: Peter R
authors.initials: PR
authors.lastname: Kowey
authors.forename: Gerald V
authors.initials: GV
authors.lastname: Naccarelli
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy*; D001562:Benzimidazoles / Q000008:administration & dosage* / Q000009:adverse effects; D002543:Cerebral Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D000069604:Dabigatran; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D018570:Risk Assessment; D020521:Stroke / Q000517:prevention & control*; D013917:Thrombin / Q000037:antagonists & inhibitors*; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence*; D015091:beta-Alanine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D000925:Anticoagulants; D001562:Benzimidazoles; D015091:beta-Alanine; D013917:Thrombin; D000069604:Dabigatran